Biallelic CEBPA mutations and FMS-like tyrosine kinase receptor 3 (FLT3) length mutations are frequently identified in human acute myeloid leukemia (AML) with normal cytogenetics. However, the molecular and cellular mechanisms of oncogene cooperation remain unclear because of a lack of disease models. We have generated an AML mouse model using knockin mouse strains to study cooperation of an internal tandem duplication (ITD) mutation in the Flt3 gene with commonly observed CCAAT/enhancer binding protein alpha (C/EBPa) mutations. This study provides evidence that FLT3 ITD cooperates in leukemogenesis by enhancing the generation of leukemia-initiating granulocyte-monocyte progenitors (GMPs) otherwise prevented by a block in differentiation and skewed lineage priming induced by biallelic C/EBPa mutations. These cellular changes are accompanied by an upregulation of hematopoietic stem cell and STAT5 target genes. By gene expression analysis in premalignant populations, we further show a role of FLT3 ITD in activating genes involved in survival/transformation and chemoresistance. Both multipotent progenitors and GMP cells contain the potential to induce AML similar to corresponding cells in human AML samples showing that this model resembles human disease.
INTRODUCTION
The two fundamental features of acute myeloid leukemia (AML) include deregulated proliferation and cell survival by activation of oncogenes or deactivation of tumor-suppressor genes, and a block of differentiation caused by reduced function of transcription factors being specifically important for terminal differentiation of cell lineages derived from the common myeloid progenitor.
1,2 Accordingly, growing evidence indicates that collaborating genetic alterations in leukemogenesis could be categorized as mutations affecting signaling pathways (class I or signaling mutations; for example, FMS-like tyrosine kinase receptor 3 (FLT3) mutations) and mutations with a transcriptional function affecting differentiation of one or several lineages (class II; for example, CEBPA mutations).
3,4 AML evolution is believed to be a process of consecutive acquisition of genetic/epigenetic changes; but it remains elusive whether the mutations leading to generation of leukemia-initiating cells (LICs), occur in hematopoietic stem or progenitor cells. Experimental approaches investigating this question have mainly been using retroviral expression of oncogenes, leading to the expression of the oncogene at inadequate levels and stages of differentiation in addition to the risk of insertional mutagenesis.
Mutations in the CEBPA gene, encoding the CCAAT/enhancer binding protein alpha (C/EBPa) transcription factor, are observed in approximately 7 --14% of de novo AML cases. 5, 6 Its complete absence in hematopoietic cells induces several effects, including a block in myeloid differentiation accompanied by severe reductions in mature myeloid cell populations, an accumulation of immature myeloid precursors in the bone marrow (BM) without progression to AML, and an enhanced self-renewal capacity of hematopoietic stem cells (HSCs). 7 Deletion of the Cebpa gene in murine HSCs was found to increase their ability to compete against wild-type HSCs. 8 However, null mutations are virtually never found in CEBPA mutant AML. Affirmatively, in the absence of C/EBPa, no AML was observed in a transgenic mouse model, probably because of the requirement of C/EBPa for myeloid lineage commitment in the pathogenesis of AML. 8, 9 The molecular mechanisms behind CEBPA mutations in AML development are not entirely clear. The spectrum of CEBPA mutations observed in AML includes N-terminal mutations blocking the translation of the 42 kDa isoform (p42) while allowing the 30 kDa isoform (p30) to be expressed, and C-terminal mutations generating in-frame insertions/deletions within the basic region leucine zipper DNA binding domain disrupting dimerization and DNA binding of both isoforms. 10 Interestingly, often both CEBPA alleles harbor mutations in AML, recurrently the combination of an N-terminal mutation at one, and a C-terminal mutation at the other allele. 10 The combination of N-and C-terminal C/EBPa mutations incorporates premalignant HSC expansion and sufficient myeloid programming to allow the formation of common myeloid progenitor-derived LICs. 11 Although mice with biallelic Cebpa mutations eventually develop AML, additional genetic changes are required for leukemogenesis as indicated by the long latency period.
Constitutive activating mutations of the FLT3 (predominantly internal tandem duplication (ITD) mutations of the juxtamembrane domain) are frequently observed in AML. 12, 13 Knockin mouse models have shown that FLT3 ITD causes suppression of lymphoid differentiation and increased proliferation of myeloid progenitors leading to a myeloproliferative phenotype without progression to AML. 14, 15 Clinical data demonstrate CEBPA mutations as a reoccurring partner in AML with FLT3 ITD. 5, 16, 17 However, there is no study investigating FLT3 ITD in cooperation with CEBPA mutations where FLT3 ITD or both oncogenes are expressed from their own promoter at the original locus.
Here, we combined three knockin mouse strains to investigate the spectrum of CEBPA mutations occurring in AML in cooperation with FLT3 ITD. One strain contains an ITD mutation in the endogenous murine Flt3 locus, 14 which was cross-bred with a knockin of an N-terminal Cebpa mutation (Lp30 or L allele) 18 and a C-terminal Cebpa mutation (K313 duplication: K313KK or K allele). 11 This model for human AML enabled us to appropriately study the molecular and cellular background of leukemia initiation and maintenance. Expressed from its original promoter, the respective leukemogenic mutations acted at the correct developmental stage and physiological levels.
MATERIALS AND METHODS

Mouse strains
The mouse strains used in this study have been described previously. 11, 14, 18 Briefly, insertion of a premature stop codon between the p42 and p30 C/EBPa start sites results in exclusive p30 C/EBPa translation (Cebpa Lp30 or L allele; Cebpa L/ þ ). The K313KK mutation was generated by insertion of an additional lysine in the C/EBPa coding sequence (Cebpa K313KK or K allele; Cebpa K/ þ ) leading to disruption of the basic region leucine zipper of C/EBPa. The Flt3 ITD/ þ knockin mice were generated by insertion of a human ITD mutation into exon 14 of the murine Flt3 locus. All mouse strains were maintained according to Swedish animal guidelines, and all experiments were approved by the Ethical Committee at Lund University (Ethical permit no. M147-09). Quantitative PCR analysis (Fluidigm)
Breeding and fetal liver transplantation
Real-time PCR analysis was performed using the nanofluidic BioMark 48.48 Dynamic Array (Fluidigm, San Francisco, CA, USA). The generation of complementary DNA and gene-specific pre-amplification were carried out using CellsDirect One-Step qRT-PCR Kit (Invitrogen AB). In all, 10 --200 cells were sorted directly into 10 ml of reaction buffer containing 5 ml CellsDirect 2 Â Reaction Mix (Invitrogen AB), 1.2 ml CellsDirect RT/Taq Mix, 1.2 ml TE buffer, 0.1 ml SUPERase-In RNase Inhibitor (Ambion, Invitrogen AB, AM2694) and 2.5 ml of a mix of 0.2 Â TaqMan Gene Expression Assay (Applied Biosystems, Invitrogen AB). Reverse transcription and specific target preamplification was carried out with the following conditions: 15 min at 50 1C followed by 2 min at 95 1C followed by 22 cycles of 95 1C for 15 s and 60 1C for 4 min. To this pre-amplified complementary DNA, 40 ml of TE buffer was added and stored at À20 1C. The Dynamic Array PCR cycling condition was 95 1C for 10 min followed by 40 cycles of 95 1C for 15 s and 60 1C for 60 s. All reactions were carried out in duplicates or triplicates. In each experiment, cell populations were sorted from two individual mice. Data were analyzed using the ddCt method and results from each experiment were normalized to the expression of hypoxanthine guanine phosphoribosyl transferase 1 (Hprt1). A mean expression level relative to a specified reference population was calculated and results were displayed as the mean normalized expression level (±s.d.) relative to the reference population derived from two experiments.
Blood and BM analysis
Peripheral blood (PB) smears and BM cytospins were prepared and stained as described elsewhere. 18 
Statistical analysis
Statistical significance was determined by Student's t-test for pairwise comparison or analysis of variance for multiple comparisons following pairwise Tukey post-hoc tests. Survival curves were tested with KaplanMeier comparisons, where the log-rank test was used. All statistical analysis was carried out with Graphpad Prism 5 for Windows (Graphpad Software, Inc., La Jolla, CA, USA).
RESULTS
Single mutations of Cebpa in cooperation with FLT3 ITD are not sufficient to initiate leukemia To study the leukemogenic potential of mono-and biallelic Cebpa mutations in cooperation with Flt3 ITD, we generated E14.5 FL cells of the following genotypes: wild-type (wt), Flt3 Figure 1A ), which were then co-transplanted with unfractionated BM cells, as support cells, into lethally irradiated recipients (Supplementary Figure 1B) . The use of FL cells was necessary because of postnatal lethality of biallelic Cebpa mutants.
Biallelic CEBPA mutations define a subgroup with distinct gene expression pattern and favorable outcome. 17 Although not having a prognostic significance, single CEBPA mutations are at least as commonly seen in AML as biallelic mutations. 17, 20 However, previous studies did not find leukemic potential in mice carrying monoallelic Cebpa L/ þ or Cebpa K/ þ mutations. 11, 18 On the other hand, it has been shown that FLT3 ITD can phosphorylate C/EBPa, which could lead to a loss of function in the absence of other mutations explaining why some AML only carry a monoallelic C/EBPa mutation. 21, 22 In addition, recent work using retroviral overexpression demonstrated that a C-terminal Cebpa mutation (C/EBPa-C m ) was sufficient to cause AML and that FLT3 ITD could shorten the latency of AML induced by C/EBPa-C m . 23 To elucidate this discrepancy, we also monitored hematopoietic chimeras with single, either N-terminal (L allele) or C-terminal
However, we did not observe incidences of leukemia during a time period similar to the latency for leukemia development in cohorts with biallelic Cebpa mutations (monitored over a period of 44 weeks; Supplementary Figure 2A) . We confirmed similar levels of chimerism as in mice transplanted with KL or KLI cells after 4 weeks in PB and BM ( Supplementary Figures 2B and D) . Importantly, the characteristic myeloid differentiation block as in KL and KLI chimeras was not observed (Supplementary Figures 2C and E) arguing against cooperation between FLT3 ITD and monoallelic C/EBPa in blocking myeloid differentiation. Obviously, monoallelic mutations do not sufficiently reduce C/EBPa function to prevent GMP development. Additionally, the hematopoietic stem and progenitor cell compartments were not found to be different from control mice (data not shown). Thus, CEBPA activity may only be leukemogenic in a certain range, with either too much or too little activity being insufficient to induce disease. Figure 3D) . After 16 weeks, this effect could also be observed in PB (Supplementary Figure 3F) . All cohorts transplanted with KL or KLI FL cells developed AML. However, we observed that mice transplanted with KLI FL cells had significantly shorter latency than the KL cohorts (KLI median survival was 22.5 weeks, while KL median survival was 33.8 weeks; Po0.001; Figure 1a ). Diseased KL and KLI mice presented high occurrence of blast cells as examined by Giemsa staining of PB and BM and extramedullary hematopoiesis causing splenomegaly (Figures 1b and d) . Further, leukemic mice showed increased white blood cell counts in PB compared with control mice although unexpectedly, there was no difference in white blood cell counts between KL and KLI chimeras (Figure 1c) . Analysis of leukemic BM at this time point revealed an immature population of Mac1 int Kit þ cells (Figure 1e ), which also infiltrated the spleen (Figure 1f ). The leukemia was transplantable into secondary recipients showing a dose-dependent latency (Supplementary Figure 5A) . As expected, the latency of secondary leukemia was much shorter than that of primary AMLs. As mutant allele-specific imbalance because of copy neutral loss of heterozygosity is a frequently occurring event, we investigated whether wt FLT3 was lost during primary AML development. 24 We examined at least seven independent samples of KLI leukemia and never observed a loss of the wt allele (Supplementary Figure 5B) Figure  3D) and the expansion of GMP in KLI compared with KL prior development of leukemia prompted us to further characterize the myeloid compartment of these chimeras at a preleukemic stage (4 --6 weeks after transplantation). We analyzed BM cells according to the cell surface marker protocol established previously for highresolution fractionation of BM progenitor compartments. 19 From (Figures 2a  and b) . Notably, the block in myeloid differentiation caused by biallelic Cebpa mutations occurred at the pGMP stage as shown before for the KL genotype.
11 Also, KLI cohorts showed reduced frequency of GMPs, although much less severe ( Â 10) than KL (Figure 2c ), while the frequency of pGMPs was further increased (Figure 2d 11 However, the addition of FLT3 ITD in KLI chimeras resulted in lower frequencies of MkP, pMegE and pCFU-E while GMP and pGMP were more frequent (Figures 2c and d) . This effect indicates that FLT3 ITD opposes the block in myeloid lineage commitment caused by Cebpa mutations.
Hematopoietic stem and progenitor expansion mediated by biallelic Cebpa mutations is amplified by FLT3 ITD In addition to hampered myeloid differentiation, it has been shown that biallelic Cebpa mutations can cause a preleukemic expansion of LIN À Sca1 þ cKit þ (LSK) cells including HSCs and MPPs mediated by decreased quiescence of Cebpa mutant phenotypic LT-HSCs and their downstream progeny. 11 In contrast, Flt3 ITD has been described to support myeloid development by suppressing megakaryocyteerythroid and B-cell development, and second to confer enhanced proliferation and survival to MPPs.
14 To answer the question of the combinatory effect of both alterations in leukemogenesis, we carried out flow cytometry-based analysis of HSC frequencies in chimeras 4--6 weeks after transplantation. Using FLT3 and CD150 surface expression to distinguish LT-HSCs (LSKCD150 Figure 4C) . KL Cebpa mutations resulted in LSK expansion with significant increase in lymphoid-primed MPP (Supplementary Figure 4D) , ST-HSC (Supplementary Figure 4E ) and LT-HSC (Supplementary Figure 4F) frequency. Addition of FLT3 ITD in KLI chimeras resulted in a further increased LSK frequency predominantly by expansion of ST-HSCs (Supplementary Figure 4E ). We also observed a higher frequency of LT-HSC in KLI chimeras (Supplementary Figure 4F) . However, there is evidence that Flt3 ITD/ þ mice have lower surface expression of the FLT3 receptor (Jacobsen, personal communication) probably due to entrapment of the FLT3 ITD in the endoplasmic reticulum 25, 26 and therefore identification of LT-and ST-HSC using FLT3 may be problematic. Consequently, we decided to rely on expression of CD150 and CD48 (Figures 3a and b) to identify LT-HSC (LSKCD150 þ CD48 À ) and MPP (CD150 À CD48 þ ). 27 Again, LSK frequencies were further increased by FLT3 ITD in KLI mice (Figure 3c ). However, we found the LT-HSC frequency of KLI mutant chimeras reduced compared with wt while it was still increased in KL mutants using SLAM surface markers (Figure 3d ). The LSK expansion in KL and KLI chimeras (Figure 3c were less frequent in KLI compared with KL mice. However, expression was not consistently different for all genes in the investigated genotypes (Figure 4b) . Nonetheless, Gata1 and Epor were significantly lower expressed in KLI LT-HSC (Figure 4b ) explaining lower MegE progenitor frequencies. The increased frequency of myeloid progenitors in KLI chimeras could not completely be explained by an increased expression of myeloid lineage-affiliated genes (Mpo, Csf1r, Csf2r and Csf3r) in the expanded MPP population. However, differential expression of Csf1r and significantly higher expression of Mpo may be supporting evidence for this phenotype in KLI chimeras (Figure 4d ). On the other hand, with upregulation of FLT3 in MPP (and FLT3 ITD in ITD/ þ and KLI chimeras) we observed an increased expression of STAT5 target genes such as Cish, Pim1 and Socs1 (Figure 4c ). STAT5 is a direct target of FLT3 ITD 29 and activation of the STAT5 pathway by FLT3 ITD was previously shown. 14 In accordance with previous data, the FLT3 ITD-related activation of STAT5 is a strong proliferative signal and probably the cause of expansion of the MPP compartment. 14, 30, 31 However, addition of FLT3 ITD in KLI cohorts had no effect on myeloid gene expression. Therefore, the higher frequency of myeloid progenitors can only be attributed to proliferative effect of FLT3 ITD. Opposite to upregulation of myeloid genes during normal transition from pGMP to GMP, we observed lower expression of Mpo and Csf1r in GMPs from Cebpa mutant chimeras (Figure 4e) . At the same time, HSC-related genes (Kit, Mpl, Gata2, Bmi1 and Meis1) were strongly upregulated (2 --50-fold) in Cebpa mutant GMP, which was further enhanced by the addition of FLT3 ITD (Figure 4g) . Especially, expression of Bmi1, which is required for self-renewal in HSCs and leukemic stem cells is elevated in GMPs. 32 Of importance in regard to chemotherapy resistance of AML is also the upregulated expression of Mcl1 in GMPs of Cebpa K/L x Flt3 ITD/ þ chimeras. Expression of the pro-survival gene Mcl1, a member of the BCL2 family and a crucial regulator of HSC survival, has been implicated in the pathogenesis of AML. 33, 34 Recent studies have shown that MCL1 contributes to chemoresistance and disease relapse. 35, 36 FLT3 ITD has been shown to stimulate MCL1 expression in HSCs and LICs via the STAT5-dependent signaling pathway. 37 Finally, the expression of genes involved in transformation and survival (Rgs2, Mycn, Myc and Mcl1; Figure 4f ) were strongly upregulated, indicating a deregulated GMP population that has partially or fully left the myeloid differentiation path and acquired HSC-like self-renewal and enhanced survival.
LIC potential resides in the committed myeloid progenitor compartment Primary mice developed fatal AML with an expanding GMP compartment (Figure 5a ). In order to address the leukemia-initiating potential in cells of distinct differentiation stage, we sorted phenotypic GMP, MPP and LT-HSC from either KL or KLI chimeras and subsequently transplanted equivalent cell numbers of each cell population (or total BM cells for comparison) into lethally irradiated recipients. We observed development of AML in mice transplanted with whole (unfractionated) BM, GMPs and MPPs from KLI mice (Figure 5b) . Transplantation of 10 immunophenotypic LT-HSCs did not cause leukemia within the monitored time period. During the time we monitored mice transplanted with cells from KL mice, we observed fatal AML in all mice transplanted with total BM or GMPs (Figure 5c ). Cohorts transplanted with MPP or HSCs from KL mice did not show signs of disease over the monitored period, probably due to low reconstitution levels. However, by transferring AML into recipient mice from sorted phenotypic GMP, we confirmed that LIC potential is retained in a population of committed progenitors similar to previous work, which demonstrated the potential to initiate leukemia from a GMP-like cell. 18, 38 Comparing cohorts that received populations from KL or KLI, we observed a shorter latency of AML development in recipients that were transplanted with the respective population from KLI mice indicating a proliferative effect of FLT3 ITD on the blast cells.
DISCUSSION
So far, AML mouse models commonly utilized retroviral delivery of at least one of the leukemic oncogenes into a target cell population that was subsequently transplanted into recipients to generate hematopoietic chimeras. This approach carries the risk of random/unknown modifications of the genome by insertional mutagenesis, which by activation of oncogenes or inactivation of tumor-suppressor genes may cooperate with the original alteration. 39 Additional problems are non-physiologic levels and expression of the oncogenes at eventually incorrect cellular differentiation stage. These drawbacks are circumvented in our study that characterizes, for the first time to our knowledge, a mouse model for AML where class I and class II mutations are both expressed from the original promoter preserving accurate levels and regulation of oncogene expression. This model gives interesting insights regarding oncogene cooperation on a cellular and molecular level.
Cooperation of Flt3
ITD/ þ and Cebpa K/L in early leukemogenesis
During the preleukemic phase ( Figure 6 ), Cebpa K/L mutations promote a modest expansion of HSCs and a much more substantial expansion of MPPs (middle panel, Figure 6 ). FLT3 ITD (and FLT3), which is expressed in MPPs and pGMPs, 40, 41 amplified this effect and caused further expansion of MPPs (right panel, Figure 6 ). Cebpa K/L mutant HSCs can upregulate erythroid-associated genes while granulocyte/ macrophage-associated genes are downregulated, resulting in a block at the pGMP stage.
11 We demonstrated at the cellular level that upregulation of the erythroid gene program causes an increase in frequency of pMegE (14-fold), MkP (17-fold), pCFU-E (10-fold) and CFU-E (3-fold) in Cebpa K/L mice while GMPs are virtually absent (21-fold reduction compared with wt, middle panel, Figure 6 ). FLT3 ITD reduced the frequency of MegE lineage-specific progenitors but increased the frequency of phenotypic pGMPs (eightfold) and GMPs (twofold reduction compared with wt, right panel, Figure 6 ) in Cebpa
ITD/ þ cohorts. However, these more frequent phenotypic GMPs were unable to activate their myeloid gene program preventing them from differentiating along the myeloid pathway (Figure 4e ). At the same time, GMPs aberrantly expressed genes that are associated with transformation/survival and self-renewal (Figures 4f and g ). This effect was further elevated in the Cebpa K/L Â Flt3 ITD/ þ background, which probably results in more rapid transformation and shorter latency to develop AML in these mice.
Surprisingly, although the disease latency was shortened by the combination of FLT3 ITD with biallelic C/EBPa mutations, it was still relatively long considering the high chimerism and all transplanted cells carrying the mutations. This argues for the requirement of additional genetic changes in the pathogenesis of AML. Additionally, it highlights the artificial effect of insertional mutagenesis in leukemogenesis in other mouse models, because we could not observe development of AML in mice expressing monoallelic C/EBPa and FLT3 ITD mutations within a time period that was sufficient to generate AML using retroviral expression of these lesions. 23 Our murine AML model mimics the human disease in many aspects as shown by morphology and phenotype. Interestingly, in contrast to the human disease, expression of FLT3 ITD in Cebpa mutant mice developing AML was not accompanied by higher white blood cell counts (Figure 1c) .
In early stages of leukemogenesis, Cebpa K/L mutations turn HSCs into expanding, developmentally skewed preleukemic HSCs by promoting proliferation and altering their differentiation program. Previous data suggested that CEBPA regulates myeloid lineage-specific genes in uncommitted HSCs. 11 Our data demonstrate the downstream cellular consequences of this skewed lineage priming in Cebpa K/L mutant HSCs. The preleukemic HSCs are primed to generate downstream myeloid cells that on acquisition of necessary secondary genetic alterations turn into cells with leukemia-initiating potential. Previous work demonstrated a distinct role of FLT3 in early myeloid development. 40 At the stage where the myeloid differentiation block occurs in our model, most pGMPs express FLT3 (or FLT3 ITD in this model). Transition from pGMP to GMP is blocked in this model during early stages of leukemogenesis. We demonstrate that FLT3 ITD has a distinct role in leukemogenesis by promoting differentiation toward a GMP with LIC properties. This effect on pGMPs and GMPs is accompanied by activation of STAT5 pathways and increased expression of genes associated with self-renewal, survival and transformation. The isolated and transplanted fraction of phenotypic GMPs caused development of leukemia in secondary recipients, which substantiates the hypothesis that LICs include committed myeloid progenitors. 18, 42, 43 Moreover, leukemic MPPs could also cause AML in secondary recipients with expansion of phenotypic GMP indicating a hierarchical order of these populations in leukemogenesis. Hence, our model confirms the premise of LICs possessing proliferative potential of a committed progenitor and acquiring self-renewal potential, which otherwise is restricted to stem cells. This committed myeloid progenitor is crucial for leukemia initiation as Cebpa knockout mice, lacking myeloid differentiation downstream of the common myeloid progenitor, do not develop AML. 8 The findings in our murine AML model are very much in accordance with observations recently made by investigating the subpopulations with leukemia-initiating potential in human AML samples. This study showed that GMPs and lymphoid-primed MPPs both had leukemia-initiating potential and that these populations are organized in a hierarchical order. 44 Our murine AML model is perfectly suited to test the effects of chemotherapy and tyrosine kinase inhibitors blocking FLT3 ITD function on specific cellular populations to investigate their specific role in relapse of leukemia after complete remission. 
